


1642

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
18467

In Re Application Of: Lloyd S. Gray et. al.



Filing Date

August 11, 2006

Examiner

Unassigned

Customer No.

23389

Group Art Unit

Unassigned

Confirmation No.

Unassigned

Title:

INHIBITING CAV3 ISOFORMS AND THE d 25B SPLICE VARIANTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
18467

In Re Application of: **Lloyd S. Gray et. al.**

Application No. 10/589,216	Filing Date August 11, 2006	Examiner Unassigned	Customer No. 23389	Group Art Unit Unassigned	Confirmation No. Unassigned
--------------------------------------	---------------------------------------	-------------------------------	------------------------------	-------------------------------------	---------------------------------------

Title:

INHIBITING CAV3 ISOFORMS AND THE d 25B SPLICE VARIANTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Signature


Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
<u>January 15, 2008</u> (Date)
_____ Signature of Person Mailing Correspondence
<u>Edward W. Grolz</u> Typed or Printed Name of Person Mailing Certificate

Dated: **January 15, 2008**

Edward W. Grolz
Reg. No. 33,705
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza Suite 300
Garden City, NY 11530
(516) 742-4343

cc: EWG/kl



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Lloyd S. Gray, et al.

Examiner: Unassigned

Serial No: 10/589,216

Art Unit: Unassigned

Filed: August 11, 2006

Docket: 18467

For: INHIBITING CAV3 ISOFORMS AND
THE δ 25B SPLICE VARIANTS FOR THE
DIAGNOSIS AND TREATMENT OF CANCER

Dated: January 15, 2008

Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 23313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 C.F.R. §§1.56, 1.97 and 1.98**

Sir:

Applicants, in order to meet their duty of disclosure, set forth at 37 C.F.R. §1.56, submit herewith those additional references which he deems relevant to the claims of the present application.

The relevant additional reference is as follows:

1. Bertolesi, G.E. et al., "The Ca^{2+} Channel Antagonists Mibefradil and Pimozide Inhibit Cell Growth via Different Cytotoxic Mechanisms", *Molecular Pharmacology*, 62: 210-219 (2002)
2. International Publication No. WO 99/29847 (17 June 1999)
3. Haverstick, D.M. et al., "Inhibition of Human Prostate Cancer Proliferation *in Vitro* and in a Mouse Model by a Compound Synthesized to Block Ca^{2+} Entry", *Cancer Research* 60: 102-1008 (2001)

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 15, 2008


Edward W. Grolz

4. Mariot, P. et al., "Overexpression of an α_{1H} ($Ca_v3.2$) T-type Calcium Channel during Neuroendocrine Differentiation of Human Prostate Cancer Cells", *The Journal of Biological Chemistry* 277(13): 10824-10833 (2002)
5. Shin, Jung-Bum, "Identification of genes involved in sensory neuron mechanotransduction", *Dissertation Zur Erlangung Des Akademischen Grades Doktorum Rerum Naturalis* [Online] 28 February 2003, pp 1-109, retrieved from the Internet: URL:http://www.diss.fu-berlin.de/2003/68/05_methods.pdf
6. Yunker, A.M.R. et al., "Immunological Characterization of T-Type Voltage-Dependent Calcium Channel $Ca_v3.1$ (Alpha1G) and $Ca_v3.3$ (Alpha1I) Isoforms Reveal Differences in Their Localization, Expression, and Neural Development", *Neuroscience* 117: 321-335 (2003)
7. International Publication No. WO2005/079316 A2 (1 September 2005)
8. Niwa, N. et al., "Immunoblotting of T-Type Ca^{2+} Channel Protein in Mouse Brain and Embryonic Heart by Using Two Antibodies against $Ca_v3.1$ Channels", *Environmental Medicine* 47:42-44 (2003)
9. International Publication No. WO 2004/000311 A2 (31 December 2003)


Applicants are also enclosing a copy of the partial European Search report citing the above-identified mentioned references. Said Search report was issued relative to the subject application's counterpart European application.

Applicants respectfully request that the above-mentioned references be made of record in the file of the present application. To that end, applicants submit herewith the aforementioned references and the completed Form PTO-1449, setting forth these references.

Applicants submit that the filing of this Information Disclosure Statement is prior to the issuance of a first office action on the merits. Therefore, no Declaration or fee is required to affect the filing of this Information Disclosure Statement.

Consideration of this Information Disclosure Statement is respectfully requested, since the information provided herein may be material to the patentability of the subject application as defined in 37 C.F.R. §1.56.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Edward W. Grolz', written over the printed name.

Edward W. Grolz

Registration No. 33,705

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343
EWG/kl